Core Viewpoint - 哈药股份 is focusing on enhancing its product offerings and operational efficiency to drive growth and maintain competitiveness in the pharmaceutical industry Group 1: Business Operations and Strategy - The company held an analyst meeting on July 24, 2023, with participation from various financial institutions, discussing its business strategies and product lines [1] - The company plans to improve sales of its key nutritional supplements, with year-on-year sales growth of 72.84% for compound calcium gluconate oral solution and 51.30% for zinc gluconate oral solution [1] - The company is adjusting its marketing strategies for GNC China, focusing on e-commerce channel development, cost management, and brand value enhancement to ensure compliance and high-quality growth [1] Group 2: Research and Development - From 2024 to 2028, the company will focus its R&D efforts on five major therapeutic areas: cardiovascular, digestive metabolism, respiratory, anti-infection, and anti-tumor, along with elderly and pediatric medications [2] - The company aims to transition its R&D strategy from a focus on generic drugs to a combination of generics and innovative products, enhancing its product line [2] - The company has already received approval for a generic drug, lactulose oral solution, and is working on several other products expected to be approved in the near future [2] Group 3: Asset Management and Operational Improvement - The company is working on integrating raw material and formulation processes to control product costs and improve competitiveness [3] - The company is actively pursuing the revitalization of idle assets at its subsidiary, 哈药集团制药总厂, and has approved plans for phased asset disposal [3] Group 4: Long-term Vision and Mission - The company's long-term strategy is to provide quality medications for public health and to become a benchmark in the Chinese pharmaceutical industry [4] - The company aims for high-quality and sustainable development, supported by a complete product and talent pipeline, brand strategy, and marketing innovation [4]

证券代码：600664 证券简称：哈药股份 编号：临 2025-027 哈药集团股份有限公司 关于控股股东股份质押的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 哈药集团股份有限公司（以下简称"公司"）控股股东哈药集团 有限公司（以下简称"哈药集团"）持有公司股份 1,173,237,023 股，占 本公司总股本的 46.58%；本次质押完成后，哈药集团累计质押股份 926,857,248 股，占其所持有公司股份总数的 79.00%，占公司总股本的 36.80%。 一、公司股份质押 公司于近日收到哈药集团的告知函，获悉哈药集团所持有的 90,264,182 股公司股份办理了质押登记手续，具体事项如下： | | 是否 | | 是否为限 | 是否 | | | | | 占其 所持 | 占公 司总 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 为控 | 本次质押 | 售股（如 | 补 ...

Core Viewpoint - The Heilongjiang Provincial Drug Administration announced the results of the GMP compliance inspections for 16 pharmaceutical companies, confirming their adherence to the 2010 revised Good Manufacturing Practice standards [3]. Group 1: Compliance Inspection Results - Heilongjiang Sanlian Pharmaceutical Co., Ltd. was inspected for its small-volume injection production line, specifically for anti-tumor drugs, and found compliant [3]. - Harbin Pharmaceutical Group's second factory was inspected for its granule and oral liquid production lines, confirming compliance [3]. - Heilongjiang Huabei Pharmaceutical Co., Ltd. was inspected for its solid dosage forms and traditional Chinese medicine extraction processes, and was found compliant [3]. Group 2: Inspection Details - The inspections were conducted between April and May 2025, with specific dates for each company listed [3]. - The inspection covered various production lines, including small-volume injections, oral liquids, and traditional Chinese medicine extracts [3]. - The results indicate a focus on ensuring quality and compliance within the pharmaceutical manufacturing sector in Heilongjiang Province [3].

Core Insights - The article discusses recent developments in the nutrition and health industry, highlighting regulatory changes, new product approvals, and market trends that could impact investment opportunities [2][3][4][5][6]. Regulatory Developments - The State Administration for Market Regulation issued a guideline clarifying the definition of commercial advertising under the Advertising Law, addressing ongoing disputes in advertising enforcement [2]. - The National Health Commission approved D-alloheptulose and four other substances as new food raw materials, indicating a push for innovation in the nutrition sector [3]. - The market regulator released multiple responses to proposals regarding health food regulations, signaling a focus on traditional Chinese medicine formulations as a potential growth area [4]. Market Trends and Investment Opportunities - Yangtuo Technology Inc. submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds for market expansion and supply chain optimization, reflecting growing investor interest in the nutrition and health sector [5]. - A report on 68 nutrition and health companies showed an average market value increase of 20% in the first half of the year, driven by rising consumer health awareness and demand for nutritional products [6]. Company Performance - New Hope Liuhe (002001) projected a net profit of 3.3 billion to 3.75 billion yuan for the first half of 2025, representing a year-on-year growth of 50% to 70% [12]. - Brother Technology (002562) expects a net profit of 60 million to 75 million yuan for the same period, marking an increase of 325% to 431% compared to the previous year [13]. New Product Launches - Guangji Pharmaceutical (000952) received a notice of administrative penalty for information disclosure violations, indicating regulatory scrutiny in the sector [14]. - TCM brand Tongrentang launched its first OTC glucosamine product, expanding its product line in the bone and joint health category [14].

重要内容提示： 哈药集团股份有限公司（以下简称"公司"）控股股东哈药集团 有限公司（以下简称"哈药集团"）持有公司股份 1,173,237,023 股，占 本 公 司 总 股 本 的 46.58% 。 本 次 解 除 质 押 前 哈 药 集 团 质 押 股 份 为 926,857,248 股，占其所持有公司股份总数的 79%，占当时公司总股本的 36.97%，本次解除质押股份为 90,264,182 股，本次解除质押后，哈药集团 累计剩余质押股份 836,593,066 股，占其所持有公司股份总数的 71.31%， 占公司总股本的 33.22%。 一、上市公司股份解除质押情况 哈药集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码:600664 证券简称:哈药股份 编号:临 2025-026 公司近日收到公司控股股东哈药集团的告知函，获悉哈药集团原质押 给中国银行股份有限公司澳门分行的部分公司股份已经办理完成了解除质 押手续，具体事项如下： 1 | 剩余被质押股份数量占 ...

Core Insights - The demand for grape seed health products is increasing due to rising living standards and health awareness among consumers [1][16] - The market size of grape seed health products in China is projected to grow from 5 billion yuan in 2019 to 9 billion yuan by 2024, with a compound annual growth rate of 12% [1][16] - Technological advancements in extraction efficiency and purity are supporting the growth of the grape seed health product market [1][16] Industry Overview - Grape seed health products are derived from grape seeds and contain beneficial components such as vitamins, minerals, amino acids, and antioxidants, offering various health benefits [3][10] - The industry can be categorized by product form (tablets, capsules, liquid), efficacy (antioxidant, anti-aging), and usage scenarios (daily health, beauty, sports nutrition) [5][10] Market Dynamics - The grape seed health product market is experiencing rapid expansion due to the growth of e-commerce and diversified marketing channels [1][16] - The increase in grape production in China, from 13.16 million tons in 2015 to 16.17 million tons in 2023, is expected to provide ample raw materials for grape seed health products [12][14] Regulatory Environment - Recent policies in China aim to promote the integration of the food industry with health and wellness sectors, enhancing the market for functional foods and health products [6][9] Competitive Landscape - Major players in the grape seed health product market include well-known domestic brands such as汤臣倍健 (Tongrentang), 康恩贝 (Kang En Bei), and 九芝堂 (Jiu Zhi Tang), as well as international brands like Nature's Way and NOW Foods [18][19] - Companies are enhancing their competitiveness through improved production technologies and brand marketing strategies [18][19] Consumer Trends - There is a notable increase in consumer demand for high-quality grape seed health products, particularly among women and young adults aged 18 to 35, who represent 83.7% of the health supplement market [24][25] - Consumers are increasingly focused on product quality, efficacy, and safety, necessitating continuous improvement in product formulations [24][25] Future Outlook - The industry is expected to benefit from technological advancements that enhance product absorption and bioavailability [25][26] - The trend of online and offline integration in sales channels is becoming crucial for market growth, providing consumers with a more convenient shopping experience [26][27] - International expansion is a growing trend, with Chinese companies leveraging their resources and technology to compete in global markets [27]

Meeting Details - The shareholders' meeting was held on June 20, 2025, at the company's third-floor conference room [1] - The meeting was convened by the board of directors and chaired by the chairman, utilizing a combination of on-site and online voting methods [1] Voting Results - All proposed resolutions were approved with significant majority votes, including: - First resolution: 1,268,756,206 votes in favor (99.6779%) [1] - Second resolution: 1,268,665,806 votes in favor (99.6708%) [1] - Third resolution: 1,265,970,906 votes in favor (99.4590%) [1] - Fourth resolution: 1,235,870,836 votes in favor (97.0943%) [1] - Fifth resolution: 1,266,313,406 votes in favor (99.4860%) [2] - Additional resolutions also received over 99% approval [2][3] Legal Compliance - The meeting and voting procedures were confirmed to comply with the Company Law, Securities Law, and relevant regulations, ensuring the legality and validity of the resolutions passed [3]

ar in a comments of /UECHENG LAW FIRM 黑龙江分所 北京岳成(黑龙江)律师事务所 关于哈药集团股份有限公司 2024 年年度股东大会的 北京 · 上海 · 广州 · 深圳 · 杭州 · 南京 · 西安 · 成都 · 重庆 · 哈尔滨 · 大庆 · 三亚 黑龙江省哈尔滨市南岗区长江路 65 号远东商务中心8层 电话:(0451) 82604902/82604903 1 / 8 京点次理 n = 分 = EIJING YUECHENG LAW FIRM 黑龙江分所 所发表的结论性意见合法、准确,不存在虚假记载、误导性陈述或者重 大遗漏,并承担相应法律责任。 鉴此,本所律师根据上述法律、法规、规则、规章及规范性文件的 要求,按照律师行业公认的业务标准、道德规范和勤勉尽责精神,对公 司本次股东大会召集及召开程序、会议召集人的资格、出席会议人员的 资格、表决程序及表决结果等重要事项的合法性进行了审核与见证,现 出具法律意见如下: 一、公司股东大会的召集与召开程序 法律意见书 致:哈药集团股份有限公司 受哈药集团股份有限公司(以下简称"公司")聘请,北京岳成(黑 龙江) 律师事务所指派 ...

(三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 481 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,272,855,797 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 50.5565 | | 份总数的比例（%） | | 证券代码：600664 证券简称：哈药股份 公告编号：2025-025 哈药集团股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 20 日 (二)股东大会召开的地点：公司三楼会议室 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，由董事长主持会议，会议采用现场投票和 网络投票相结合的方式召开，会议的召集、召开和表决方式符合《公司法》及《公 司章程》的有关规定。 (五) ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-024 剂型：胶囊剂 规格：0.1g 近日，哈药集团股份有限公司（以下简称"公司"）所属企业哈 药集团制药总厂（以下简称"哈药总厂"）收到国家药品监督管理局 颁发的关于诺氟沙星胶囊的《药品补充申请批准通知书》【编号： 2025B02670】，本品通过仿制药质量和疗效一致性评价。 药品名称：诺氟沙星胶囊 哈药集团股份有限公司 关于所属企业药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 申请人：哈药集团制药总厂 原药品批准文号：国药准字 H23020934 一、 药品的基本情况 审批结论：本品通过仿制药质量和疗效一致性评价 截至本公告日，哈药总厂对该药品仿制药质量和疗效一致性评价 已投入研发费用约 759.72 万元人民币（未经审计）。 三、 对上市公司影响及风险提示 根据国家相关政策，通过仿制药质量和疗效一致性评价的药品品 种在医保支付及医疗机构采购等领域将获得更大的支持力度。本次哈 药总厂的诺氟沙星胶囊（0.1g）通过仿制药质量和疗效 ...